Glycosmedia Weekly Diabetes News Update
View this email in your browser

Platinum Sponsors:

Boehringer Ingelheim Lilly

Gold Sponsors:

Novo Nordisk

AstraZeneca

Silver Sponsors:
 

Abbott Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 10/02/2020

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19

In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (Diabetes Care)


Next steps in the identification of gene targets for type 1 diabetes

The purpose of this review is to provide a view of the future of genomics and other omics approaches in defining the genetic contribution to all stages of risk of type 1 diabetes and the functional impact and clinical implementations of the associated variants (Diabetologia)


Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects

Soluble EGFR, a hepatokine, is correlated with insulin resistance in the liver, while adipsin, an adipokine, is associated with adipose insulin resistance (Diabetology & Metabolic Syndrome)


Alterations of Gut Microbiota in Type 2 Diabetes Individuals and the Confounding Effect of Antidiabetic Agents

The findings of this study have added a novel understanding about the pathogenesis of the disease and the mechanisms underlying antidiabetic therapy, which are of potential interest for therapeutic lines and further studies (Journal of Diabetes Research)


The Digital/Virtual Diabetes Clinic: The Future Is Now

Recommendations from an International Panel on Diabetes Digital Technologies Introduction (Diabetes Technology and Therapeutics)


Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study

Real-life population-based data suggest a positive effect of metformin on depression rates. This evidence should be used in guiding prescriptions for patients with type 2 diabetes who are at risk for developing depression, including those with prior depression or anxiety and patients with a family history of depression (Diabetes Care)


Modeling Carbohydrate Counting Error in Type 1 Diabetes Management

The most important predictors of CHO counting errors are CHO and meal type. The mathematical models proposed improve the description of patients’ behavior in the T1D patient decision simulator (Diabetes Technology and Therapeutics)


Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial

Eighteen months of metformin treatment in combination with insulin compared with insulin alone increased early drop in OBP indicating an adverse effect of metformin on CAN independent of vitamin B12, MMA HbA1c (Cardiovascular Diabetology)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2020 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp